GSK575594A 、 乙酸酐 在
碳酸氢钠 作用下,
反应 16.0h,
以to afford on evaporation the title compound as a white solid 173 mg, 80%的产率得到N-[3-fluoro-4-(4-{[4'-fluoro-4-(methylsulfonyl)-2-biphenylyl]carbonyl}-1-piperazinyl)phenyl]acetamide
参考文献:
名称:
Acylated Piperidines as Glycine Transporter Inhibitors
ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS
申请人:GLAXO GROUP LIMITED
公开号:EP1858869A1
公开(公告)日:2007-11-28
METHODS AND COMPOSITIONS FOR TREATING AND RECOVERING FROM VIRAL INFECTIONS
申请人:IMMUNOFLEX THERAPEUTICS INC.
公开号:US20210369661A1
公开(公告)日:2021-12-02
The described invention provides compositions and methods for improving or restoring immune system health in a susceptible subject and/or a subject infected with a respiratory virus that impacts the immune system by reducing functional diversity of T cells and promoting T cell exhaustion, compared to a control.
[EN] ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS<br/>[FR] PIPÉRIDINES ACYLÉES EN TANT QU'INHIBITEURS DE TRANSPORTEURS DE GLYCINE
申请人:GLAXO GROUP LTD
公开号:WO2006094842A1
公开(公告)日:2006-09-14
[EN] The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R1, n, X, Y and Z are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia. [FR] L'invention concerne un composé de la formule (I) ou un sel ou un solvate de celui-ci : où R1, n, X, Y et Z sont tels que définis dans la description, et les utilisations de tels composés. Les composés inhibent les transporteurs de GlyT1 et sont utiles dans le traitement de certains troubles neurologiques et neuropsychiatriques, y compris la schizophrénie.
[EN] METHODS AND COMPOSITIONS FOR TREATING AND RECOVERING FORM VIRAL INFECTIONS<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT ET LA RÉCUPÉRATION D'INFECTIONS VIRALES
申请人:IMMUNOFLEX THERAPEUTICS INC
公开号:WO2021243093A1
公开(公告)日:2021-12-02
The described invention provides compositions and methods for improving or restoring immune system health in a susceptible subject and/or a subject infected with a respiratory virus that impacts the immune system by reducing functional diversity of T cells and promoting T cell exhaustion, compared to a control.